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Abstract 
 
PURPOSE: To evaluate the role of Diffusion-Weighted MR Imaging (DW-MRI) in the 
detection of pelvic lymph node metastases in patients with prostate cancer (PC) 
candidate to radical prostatectomy and extended pelvic lymph node dissection. 
MATERIALS AND METHODS: From June 2011 to March 2012, 5 patients (median 
age: 67,2 years; range 56-76 years) with prostate cancer (high/intermediate risk patients, 
according to D’Amico Risk Groups), underwent MRI before surgical treatment using a 
3T device and a 8 channel phased-array surface body coil. Imaging protocol included 
T2-weighted FSE, T1-weighted FSE and DWI sequence (b-values: 0, 500, 800, 1000 
and 1500 s/mm2). The appearance of benign and metastatic lymph nodes on the FSE MR 
images was analyzed by two observers in conference. The measurement of the ADC 
value was performed by another radiologist, in the following nodal stations: proximal 
and distal external iliac, proximal and distal internal iliac and obturatory, each on both 
right and left sides. 
RESULTS: A total of 84 lymph nodes were removed during surgery (median: 16,8 
lymph nodes per patient, range: 12 – 23 per patient) and histologically analysed. A total 
of 46 nodal stations underwent surgical resection and histopathological examination. 
The smallest metastatic lymph node detected by this method measured 4mm on its short 
axis. The appearance of benign and metastatic lymph nodes on the FSE MR images was 
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documented in terms of short axis, the long to short axis ratio, node contour and 
intranodal heterogeneity signal intensity, in all ten nodal stations. For each of these 
parameters a grading score system was assigned using a two-point-level score and the 
grade system was obtained by adding the point-level obtained for each of these 4 
parameters. The Grading Score ranged from 4, indicator of a benign nature, to 8, with 8 
having the worst score indicator of malignant nature. The mean Grading Score was 6,46 
± 0,42 in the nodal metastatic group and 5,02 ± 0,59 in the nodal non-metastatic group 
(P < 0.0001). A Grading Score > 4 was considered suspicious for malignancy.  
With the threshold score of 4, the lymph node station-based sensitivity, specificity, 
positive and negative predictive values and diagnostic accuracy for FSE-MRI analysis, 
were 100%, 19%, 29%, 100% and 39%, respectively.  
Mean ADC value was 0.796 ± 0,09 × 10 – 3 mm2 /s in the nodal metastatic group and 
1,17 ± 0,25 × 10 – 3 mm2 /s in the nodal non-metastatic group ( P = 0.0008). 
The ADC cut-off value, obtained by the ROC curve was 0.91 × 10 – 3 mm2 /s. 
Lymph node stations-based sensitivity, specificity, PPV, NPV and diagnostic accuracy  
for DW analysis, were 100%, 95,2%, 87,5%, 100% and 96,4%, respectively.   
CONCLUSIONS: Our preliminary data seem to suggest that DW-MRI of lymph nodes 
can now be performed as part of a primary tumour staging without significantly 
increasing the imaging time. This unique modality can help to distinguish benign from 
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malignant lymph nodes and is more accurate than FSE-MRI evaluation alone. Further, 
large scale studies are certainly needed to confirm our initial results. 
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Introduction 
 
The presence of pelvic lymph node (LN) metastases in patients with prostate cancer 
(PC) is of major relevance and is decisive for treatment planning. 
Currently, pelvic lymph node dissection (PLND) represents the most accurate and 
reliable staging procedure for the detection of lymph node invasion in PC, but not all 
patients are at the same risk of harbouring pelvic LN metastases [1]. The radical 
prostatectomy with the pelvic lymph node dissection, represents a time consuming and 
relatively expensive procedure that requires inpatient hospitalization and restricted 
activity during a period of postoperative recovery. It is also associated with potentially 
early postoperative complications (bleeding, infections and lymphocele) and late 
postoperative complications (urinary incontinence, erectile deficit, anastomotic 
stenosis). For this reason, non-invasive imaging is important to streamline surgical 
resection protocol and it might be of great help in selecting patients who are suitable for 
PLND. 
Certainly, the ideal imaging modality should fulfil some key criteria including accuracy, 
reproducibility, availability, cost effectiveness and efficiency. Unfortunately, none of the 
standard preoperative radiologic techniques available to date includes all of these 
parameters and the presence of lymph node metastases and thus prediction of nodal 
malignancy remains one of the most important challenges in treatment and prognosis of 
patients with PC. Until now, LN staging is routinely performed by conventional cross-
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sectional imaging such as computed tomography (CT) and it is based on their 
morphological appearances, such as nodal size,  with a threshold of 10 mm in short axis 
diameter or clusters of smaller regional LNs, the long to short axis ratio, borders 
(lobulated or spiculated), extracapsular spread and abnormal internal architecture (such 
as central necrosis) [2]. Some innovative techniques have been introduced in order to 
overcome this clinically significant staging problem. 
Diffusion-weighted MR is a non-invasive imaging technique that yields tissue diffusion 
properties, thereby providing structural information on the underlying tissue. It has 
shown a high sensitivity and specificity for the detection and characterization of LN 
metastases of head and neck cancers [3] and it has been recently introduced as a 
promising technique for pelvic neoplasm, with only preliminary experience in PC.  
DW-MRI aims to study the random thermal motion of water molecules (Brownian 
motion), and this is generally limited in neoplastic tissues because of the high cell 
density and abundance of intra- and inter-cellular membranes.  
The mobility is then quantified by calculating the apparent diffusion coefficient (ADC).  
Conventionally, restricted diffusion in areas of high cellular density (e.g. tumours) 
exhibits low ADC values compared with less densely cellular areas in which higher 
ADC values are exhibited. But at the qualitative analysis, the brightness of lymph nodes 
on high b-value images must not be misdiagnosed because also reactive nodal 
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hyperplasia can result in increased cellularity and can exhibit a range of high signal 
intensities on DW-MRI. 
In clinical practice, DW-MRI of the lymph nodes is performed using at least two or 
more b-values. A high b-value is applied to eliminate background signal to make the 
cellular lymph nodes more conspicuous [4]. Metastatic lymph nodes often have 
increased cellularity density and consequently lower ADC; although, some metastatic 
disease can result in central nodal necrosis and ADC increase. Reduced ADC values 
may be also observed in fibrosis. 
Therefore, using quantitative ADC evaluation, pre-surgical assessment based on ADC 
threshold values may be valuable, but must be interpreted with caution given the varying 
cut-off values for malignancy published in the literature. Moreover, necrotic areas and 
inflammatory nodal hyperplasia accompanied by increased cellularity and nodal 
heterogeneity remain limitations when ADC values are applied to characterize nodal 
disease. However, DW-MRI appears to be a promising, non-invasive technique to detect 
pelvic LN metastases even in normal sized LN [2].  
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Purpose 
The aim of our study was to evaluate the feasibility and accuracy of preoperative DW-
MRI for detection of pelvic metastatic lymph nodes in a cohort of patients with PC who 
were selected for radical prostatectomy (RP) and pelvic lymph node dissection (PLND). 
 
Patients and Methods 
Between June 2011 and March 2012, 5 consecutive patients (median age: 67,2 years; 
range 56-76 years) with histologically proven PC (high or intermediate risk patients, 
according to D'Amico Risk Groups, Table 1) and scheduled for RP and PLND, 
underwent DW-MRI before surgery. 
 
Exclusion criteria: 
• bone metastases on bone scan; 
• previous treatment for PC; 
• previous/concomitant malignancy; 
• contraindications to MRI. 
 
All patients were examined on a 3T MRI unit (DISCOVERY MR750; GE Healthcare) 
and a phase array surface coil (8 channel; gradient field strength 50 mT/m; slew rate 200 
T/m/s) focused on the inferior abdomen was used. The entire pelvis, from the aortic 
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bifurcation to the pubic symphysis, was studied by application of the following 
sequences: breath-hold, fast spin echo (FSE) T1-weighted sequence (TR 600-800 ms, 
TE 6-7 ms, slice section 4 mm, spacing 0,4 mm) acquired in the transverse plain; breath-
hold, FSE T2-weighted sequence (TR 5000-8000 ms, TE 80-85 ms, slice section 4mm, 
spacing 0,4 mm) acquired in the transverse plain; breath-hold, 3D T2 acquired in the 
transverse plain (TR 2000 ms, TE 90-93 ms, slice section 2,20 mm, spacing 1,10 mm); 
DW sequences (single-shot spin-echo echo-planar imaging), acquired with respiratory 
gating in the transverse plain, using multiple b-values sequence (b-values: 0, 500, 800, 
1000 and 1500 s/mm2) (repetition time automatically adapted to the patient's breathing 
pattern, 3500-9200 ms, TE 65-69 ms, slice section 4 mm, spacing 0,4 mm, Nex 4). 
Acquisition time for the whole examination ranged from 30 to 40 min; DWI multiple  b-
values acquisition lasted no more than 6 min.  
The lymph nodes were noted on an anatomic landmark chart divided into ten different 
anatomic regions (external iliac proximal and distal, internal iliac proximal and distal 
and obturatory, each on both right and left sides). 
All patients underwent radical prostatectomy with extended lymphadenectomy, 
inclusive of the ten different nodal stations in 3 patients. In 2 patients internal iliac 
proximal and distal on both right and left sides, were not removed due 
to intraoperative difficulties. In one patients the lymphadenectomy also included the 
common iliac right station. 
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Pelvic LNs were submitted separately for pathologic assessment according to their 
anatomic location and underwent a thorough pathologic examination in order not to miss 
any metastatic deposit. A pathologist with more than 15 years of experience in 
urogenital pathology was responsible for performing all pathological examinations. The 
pathologist received an anatomical chart recording the dissected nodal stations. If no 
nodes were found, the entire tissue underwent histopathological examination. 
Conventional MR images were read at the time of patient inclusion. The radiologist was 
blinded to histopathological findings and the pathologist was blinded to DW-MRI 
results. 
The appearance of benign and metastatic lymph nodes on the FSE MR images was 
analyzed by two observers in conference in terms of short axis, the long to short axis 
ratio, node contour and intranodal heterogeneity signal intensity (evaluated on T2-
weighted images), in all ten nodal stations. For each of these parameters, a Grading 
Score system (Table 2) was assigned, using a two-point-level score and the grade system 
was obtained by adding the point-level obtained for each of these 4 parameters: short 
axis ≤ 10 mm (point 1),  short axis  > 10 mm (point 2), the long to short axis ratio ≥ 2 
(point 1),  the long to short axis ratio < 2  (point 2), regular node contour (point 1), 
irregular node contour (point 2), intranodal homogeneous signal intensity (point 1),  
intranodal heterogeneous signal intensity (point 2). The Grading Score ranged from 4, 
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indicator of a benign nature, to 8, with 8 having the worst score indicator of a malignant 
nature.  
The ADC measurements were performed by another radiologist expert in DWI of the 
abdomen. The reviewer included only nodal stations that showed a minimum of one 
node with a long axis greater than 4 mm, in order to reduce the effect of partial volume 
artefacts. A region of interest (ROI) as larger as possible inside the lymph node was 
utilized. The ADC values of LNs were calculated by multiple b-values sequence 
combining 0, 500, 800, 1000 and 1500 s/mm2. 
 
Statistical Analysis 
For each patient ( n = 5) and each pelvic side ( n = 28) the Student’s t test was used to 
compare the ADC value measured in the nodal stations in which a metastatic node was 
detected upon histopathological analysis ( n = 7) and in the nodal stations in which non-
metastatic nodes were detected upon histopathological analysis ( n = 21). The Student’s t 
test was also used to compare the Grading Score calculated in the nodal metastatic group 
and in the nodal non-metastatic group. 
Results were considered to be significant with P < 0.05. To evaluate the diagnostic 
performance of the ADC in differentiating metastatic from non metastatic lymph nodes, 
the receiver operating characteristic (ROC) curve analysis was performed. From the 
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ROC curve, the optimal threshold, the value that showed the best separation between 
metastatic and non-metastatic lymph nodes, was extracted. 
The sensitivity, specificity, positive predictive value (PPV), and negative predictive 
value (NPV) and diagnostic accuracy, were calculated for DW and FSE-MRI analysis. 
 
Results 
All patients ( n = 5) well tolerated the MRI examination. A total of 84 lymph nodes were 
removed during surgery (median: 16,8 lymph nodes per patient, range: 12–23 per 
patient) and histologically analysed. A total of 46 nodal stations underwent surgical 
resection and histopathological examination. On DW-MRI only 53 lymph nodes and 28 
nodal stations were evaluated, since only nodes with long axis > 4 mm were included in 
the image analysis (Table 3).  
Demographic and biometric information are summarized in Table 4. 
Two of 5 patients (prevalence 40%) had lymph node metastases in 7 of  28 nodal 
stations. 
The mean Grading Score was 6,46 ± 0,42 (range, 6-7) in the nodal metastatic group and 
5,02 ± 0,59 (range 4-6) in the nodal non-metastatic group (P < 0.0001) (Table 5) but a 
Grading Score = 4 (highly indicator of a benign nature) was found in only 4/21 nodal 
stations of the nodal non-metastatic group; the last 17 nodal stations showed a Grading 
Score > 4. A Grading Score > 4 was considered suspicious for malignancy. In the nodal 
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metastatic group, all nodal stations showed a Grading Score ≥ 6. With the threshold 
score of 4, the lymph node station-based sensitivity, specificity, positive and negative 
predictive values and diagnostic accuracy for FSE-MRI analysis, were 100%, 19%, 
29%, 100% and 39%, respectively.  
All of the lymph nodes in the nodal metastatic group, detected with FSE MR imaging, 
were < 10 mm in their short axis. The lymph node mean diameter (short axis) in the 
nodal metastatic group and in the nodal non-metastatic group was respectively 6,35 ± 
1,54 mm (4-9mm) and 5,08 ± 1,32mm (3-13,5mm). One patient had one benign lymph 
nodes larger than 10 mm (13,5mm) in its short axis.  
For each lymph node at least 3 measurements were made and the lowest ADC value 
recorded was chosen. The mean ADC value was 0.796 ± 0,09 × 10 – 3 mm2 /s in the 
nodal metastatic group and 1.17 ± 0,25 × 10 – 3 mm2 /s in the nodal non-metastatic group 
( P = 0.0008) (Table 6). 
The area under the ROC curve indicating the difference between metastatic and non-
metastatic lymph node values was 0.96 (Table 7). 
The ADC threshold value, obtained from the ROC curve to show the clearest separation 
between metastatic and non-metastatic lymph nodes, was 0.91 × 10 – 3 mm2 /s; 
accordingly, an ADC equal to or less than 0.91 × 10 – 3 mm2 /s was considered to be a 
metastatic lymph node (Table 8, 9). 
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With the threshold value from the ROC curve, the lymph node station-based sensitivity, 
specificity, positive and negative predictive values and diagnostic accuracy for DW 
analysis, were 100%, 95,2%, 87.5%, 100% and 96,4%, respectively. 
Examples of benign and malignant lymph nodes evaluation are reported on Figures 1, 2 
and 3. 
 
Discussion  
The assessment of prostate nodal metastases remains a difficult task and the extent of 
pelvic lymph node dissection (limited vs extended) and the most suitable candidates for 
this procedure are still a matter of intense debate. Preoperative detection of lymph node 
metastases in patients with prostate cancer is crucial for selection of the appropriate 
treatment strategy and thus for patient prognosis. Some authors base their decision with 
regard to the need for PLND on preoperative nomograms based mainly on routinely 
available preoperative variables [5-7]. This clearly allows identification of those patients 
for whom routine staging PLND might be omitted. Others favour performing PLND in 
all patients who are candidates for radical prostatectomy, regardless of baseline tumour 
characteristics [8]. This option is clearly associated with higher staging accuracy, 
especially if an extended template is adopted. Nevertheless, the staging benefit is 
balanced by the risk of exposing a certain number of patients to significant and 
potentially unnecessary PLND-related complications. The conventional cross-sectional 
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imaging such as computed tomography (CT) can not accurately differentiate between 
benign and malignant lymph nodes, especially in smaller size nodes (5-10mm) so that 
smaller metastases often go undetected. Reported CT sensitivity for the detection of 
lymph node metastases in the range of about 35% [9]. Similarly, standard MRI, dynamic 
contrast-enhanced MRI and even magnetic resonance spectroscopic imaging have 
shown no advantage over CT to predict the presence of LN infiltration [10-11]. Indeed, 
recent studies have shown that meticulous lymph node dissection in patients with PC 
discloses a high rate of metastases up to 25% in patients with preoperatively negative 
standard imaging studies [12]. Usually, pelvic nodes greater than 10 mm in the 
maximum short axis diameter are considered metastatic [13-14].  
The 18F-FDG (the most extensively used tracer in PET imaging) has shown low 
sensitivity in identifying prostate cancer, and its physiological urinary excretion reduces 
specificity in the staging of loco-regional disease. (11)C-choline tracer accumulates in 
the membranes of both normal and abnormal prostate cells and then the use of PET 
with choline, is limited to the evaluation of patients undergoing radical prostatectomy 
[15]. Therefore, (11)C-choline positron emission tomography (PET) has been 
investigated with inconclusive results.  
Single photon emission CT  fused with CT or MRI allowed a more precise localization 
of 99mTc-containing lymph nodes by improving spatial resolution and orientation in 
one study [16]. Although this modality appears promising, it is time-consuming, 
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expensive and dependent on the skills of the nuclear medicine specialist [17]. In 
addition, technetium uptake can be compromised in bulky nodal disease, in which  over 
one third of positive nodes remain unidentified [16].  
The use of lymphotropic ultrasmall superparamagnetic particles of iron oxide (USPIO) 
as a contrast agent for MRI has also been recently evaluated. In a study including 80 
men with clinically localized PC, this technique was shown to increase the sensitivity for 
detecting lymph node metastases from 35% when using MRI alone to 90% [18]. 
However, the reading of this technique is time-consuming, since a node-by-node 
comparison must be made between the native MRI and a second MRI after contrast 
agent, and requires special expertise. Moreover, it cannot overcome the problem of 
false-negative normal-sized LN harbouring micrometastases. Besides, recent studies 
have been conducted when applying super-paramagnetic particles of iron oxide and 
Diffusion-Weighted sequence (DW-MRI) [18]. In normal lymph nodes, the uptake of 
iron oxide particles by macrophages produces a signal decrease on T2/T2*-weighted 
magnetic resonance sequences, so improving diagnostic accuracy. The combination of 
two effects (reduced diffusion together with relatively unchanged T2/T2* after USPIO 
in malignant lymph nodes) leads to hyperintense signals and thus to a possibly better 
separation from normal lymph nodes, which are supposed to become invisible due to 
reduced T2/T2*. Unfortunately, these agents are not yet available in the daily clinical 
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practice [19]. For lymph node evaluation, functional MRI, and in particular DW  
imaging, represents one of the most interesting fields of research. 
Diffusion-weighted imaging (DWI) derives its contrast from the regional differences in 
the mobility of water molecules. The ADC is a quantitative parameter that reflects the 
diffusion of water and tissue perfusion. DWI has been investigated for use in 
differentiating benign from malignant lymph nodes in head and neck carcinomas. It has 
been anticipated that ADC may improve the diagnostic performance of MR in the 
detection of metastatic lymph nodes on the basis of a lower ADC value in cancer tissue 
than in non-cancerous tissue. Moreover, only small groups of patients have been 
investigated and discrepancies exist between different authors [20]. 
On the basis of our preliminary experience high-quality DW-MRI of lymph nodes 
should be performed as part of a primary tumour staging without significantly increasing 
the imaging time. This unique modality can help to distinguish benign from malignant 
lymph nodes and has achieved promising NPV values in our study group. In addition, 
the ADC based on DW imaging shows an advantage over CT, MRI and PET since the 
measurement of the ADC is relatively unrelated to the lesion size if the region of  
interest is placed inside the lymph node. Recent preliminary studies on patients with 
head and neck cancers have reported that DWI can depict metastatic cervical lymph 
nodes from benign lymphadenopathies and nodal lymphomas with a high degree of 
accuracy [21-22]. All authors have reported significant differences in ADC between 
                                                                                                                                                                              19
metastatic and normal lymph nodes. However, some discrepancies exist between those 
different studies concerning the level of ADC value provided. Razek et al. [21] reported 
that metastatic lymph nodes have lower ADC values than benign lymph nodes. On the 
contrary, Sumi et al. [22] observed a significant elevation of ADC compared with 
benign lymphadenopathy. A large spectrum of ADC values among metastatic lymph 
nodes was presented and can be explained by differences in the cellular composition of 
tumours. The higher ADC value observed in metastatic nodes can be explained by the 
presence of a necrotic part that exhibits high ADC values because of the free diffusion 
of water. The development of fibrous tissue which produced restriction of water 
diffusion is another potential cause of ADC variation [20]. When comparing ADC 
values in the literature for any organ and lesion, attention has also to be paid to the 
choice of the underlying b-value, because the mobility is quantified by calculating the 
ADC, which depends mainly on the choice of the underlying b-values [17] . 
However, to ensure accurate nodal assessment, it is important to be aware of the 
potential pitfalls of DW-MRI imaging and to review findings in conjunction with 
morphological sequences for anatomical localization and correlation of radiologic 
findings with histopathology. Potential pitfalls and limitations of DW-MRI for nodal 
assessment should be borne in mind when applying the technique for evaluation: 
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1. Small nodes (< 4 mm in long axis diameter) may be visualized using DW-MRI and 
anatomically localized but the presence of malignant disease cannot be always 
established using the technique. 
2. The ADC measurements of normal-sized lymph nodes may be degraded by partial 
volume effects. 
3. Necrotic areas in neoplastic nodes may lead to false-negative results due to the 
resultant ADC increase. Necrotic deposits therefore must be excluded. 
4. Decrease in nodal ADC value may result from nodal reactive changes. 
5. Instrumental factors such as image noise, motion artefacts can lead to systematic or 
random ADC quantification errors. 
6. Micrometastases in smaller lymph nodes with insufficient intra-nodal tumour burden 
may not impede water diffusion and can lead to false-negative results [2]. 
Our interest focused on nodal staging (N) because of the crucial prognostic value. Our 
preliminary results showed that the ADC value of metastatic lymph nodes was 
significantly lower than that of the non-metastatic lymph nodes with a positive 
predictive value of 87,5%. As regards as the FSE-MRI analysis, we found a significant 
difference between the Grading Score in the nodal metastatic group and in the nodal 
non-metastatic group, but a very low specificity, positive predictive value and diagnostic 
accuracy were observed. We also noted that the mean diameter (short axis) of the lymph 
node in the nodal metastatic group was lower than 10 mm (6,35 ± 1,54 mm; range 4-
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9mm), that is the standard cut-off reported in the literature for the pelvic lymph nodes 
[23-24]. 
However, the fact that this reflects our initial experience should be taken into 
consideration. In addition, to our knowledge, no other study has specifically investigated 
nodal metastases in prostate cancer using DW-MRI with the ADC measurement using 
the multiple b-values sequence. Moreover, a higher field strength (3T versus 1.5T) 
should allow an increase in spatial resolution and an improved signal-to-noise ratio. 
There are some limitations to this study. First, our number of patients and in particular 
those which with malignant nodes remains relatively low. Second, we recorded only 
lymph nodes larger than 4 mm in theirs long axis. Obviously lymph nodes smaller than 4 
mm can be malignant too. Third, the major limitation of this work was that it was a 
station-by-station analysis and not a node-by-node analysis.  
In conclusion, the results were encouraging and our preliminary experience with ADC 
measurements of pelvic lymph nodes of patients with prostate cancer indicated that 
ADC can help to differentiate metastatic from non metastatic lymph nodes and that it is 
more accurate than FSE-MRI evaluation alone. 
Nevertheless, a number of published studies have testified the potential of the technique 
and inter- and intra-observer reproducibility of nodal ADC measurements still needs to 
be determined to ensure that serial comparison of measurements is clinically meaningful 
[2]. 
                                                                                                                                                                              22
References 
 
[1]. Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on Prostate Cancer. Part 
1: Screening, Diagnosis and Treatment of Clinically Localised Disease. Eur Urol.2011; 
59: 61-71. 
[2]. Baert A.L, Reiser M.F, Hricak H, Knauth M, Koh D.M, Thoeny H.C. (Editors) 
Diffusion Weighted MR imaging. Applications in the body. Springer-Verlag Berlin 
Heidelberg 2010. 
[3]. Thoeny HC. Diffusion-weighted MRI in head and neck radiology: applications in 
oncology. Cancer maging 2011; 10: 209-14. 
[4]. Ahmed Abdel Khalek Abdel Razek, Sahar Elkammary, Ahmed Saad Elmorsy, et al. 
Characterization of mediastinal lymphadenopathy with diffusion-weighted imaging. MR 
Imaging 2011; 29: 167-172. 
[5]. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram 
identifying decreased risk of positive pelvic lymph nodes in patients with prostate 
cancer. J Urol 2003; 170: 1798-803. 
[6]. Briganti A, Chun FK-H, Salonia A, et al. Validation of a nomogram predicting the 
probability of lympn node invasion among patients undergoing radical prostatectomy 
and extended pelvic lymphadenectomy. Eur Urol 2006; 49: 1019-27. 
                                                                                                                                                                              23
[7]. Briganti A, Karakiewicz P, Chun FK-H, et al. Percentage of positive biopsy cores 
can improve the ability to predict lymph node invasion in patients undergoing radical 
prostatectomy and extended pelvic lymph node dissection. Eur Urol 2007; 51: 1573-81. 
[8]. Burkhard FC, Schumacher MC, Studer UE. An extended pelvic lymph node 
dissection should be performed in most patients if radical prostatectomy is truly 
indicated. Nat Clin Pract Urol 2006; 3: 454-5. 
[9]. Wolf Jr JS, Cher M, Dall’era M, Presti Jr JC, Hricak H, Carroll PR. The use and 
accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of 
pelvic lymph node metastases before radical prostatectomy. J Urol 1995; 153: 993-9. 
[10]. Tempany CM, McNeil BJ, Advances in biomedical imaging. JAMA 2001; 285: 
562-7. 
[11]. Katz S, Rosen M, MR imaging and MR spectroscopy in prostate cancer 
management. Radiol Clin North Am 2006; 44: 723-34. 
[12]. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good 
outcome for patients with few lymph node metastases after radical retropubic 
prostatectomy. Eur Urol 2008; 54: 344-52. 
[13]. Barentsz JO, Engelbrecht MR, Witjes JA, de la Rosette JJ, van der Graaf M. MR 
imaging of the male pelvis. Eur Radiol 1999; 9: 1722-36. 
[14]. Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph nodes: 
criteria for normal size determined with CT. Radiology 1991; 180: 319-22. 
                                                                                                                                                                              24
[15]. Budiharto T, Joniau S, Lerut E, et al. Prospective Evaluation of (11)C-
CholinePositron Emission Tomography/Computed Tomography and Diffusion-
Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a 
High Risk of LymphNode Metastases. Eur Urol. 2011 Jul;60(1):125-30. 
[16]. Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary 
lymphatic landing sites of the prostate should be revisited: results of a multimodality 
mapping study. Eur Urol 2008; 53: 118-25. 
[17]. Warncke SH, Mattei A, Fuechsel FG, Z’Brun S, Krause T, Studer UE. Detection 
rate and operating time required for gamma probe-guided sentinel lymph node resection 
after injection of technetium-99m nanocolloid into the prostate with and without 
preoperative imaging. Eur Urol 2007; 52: 126-32. 
[18]. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically 
occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-9. 
[19]. Thoeny HC, Triantafyllou M, et al. Combined Ultrasmall Superparamagnetic 
Particles of Iron Oxide-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging 
Reliably Detect Pelvic Lymph node Metastases in Normal-Sized of Bladder and Prostate 
Cancer Patients. Eur Urol 2009; 761-769. 
[20]. Roy C,  Bierry G, Matau A et al. Value of diffusion-weighted imaging to detect 
small malignant pelvic lymph nodes at 3 T. Eur Radiol (2010) 20: 1803–1811. 
                                                                                                                                                                              25
[21]. Razek A, Soliman NY, Elkharaway S, Tawfik A. Role of diffusion-weighted MR 
imaging in cervical lymphadenopathy. Eur Radiol (2006)16:1468–1477. 
[22]. Sumi M, Cauteren MV, Nakamura T. MR micro imaging of benign and malignant 
nodes in the neck. AJR Am J Roentgenol (2006) 186:749–757. 
[23]. Giannarini G, Petralia G, Thoeny H. C. Potential and limitations of Diffusion-
Weighted Magnetic Resonance Imaging in Kidney, Prostate and Bladder Cancer 
Including Pelvic Lymph Node Staging: A Critical Analysis of the Literature. Eur Urol 
2012; 326-340. 
[24]. Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph 
nodes: evaluation with CT after bipedal lymphangiography. Radiology 1995 
Sep;196(3):800. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                              26
Tables 
 
Table 1. D’Amico Risk Groups 
 
HIGH RISK PATIENTS • PSA* > 20 or Gleason ≥ 8 or are in clinical 
stage T2c-3a 
INTERMEDIATE RISK 
PATIENTS 
• Gleason score of 7 or PSA of 10-20 or are in 
clinical stage T2b   
LOW RISK PATIENTS • PSA ≤ 10ng/ml and Gleason score ≤ 6 or are 
in clinical stage T1-2a 
PSA* = prostate-specific antigen; ng/ml 
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Table 2: Grading Score system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Point 1 Point 2 
Intranodal 
signal intensity 
(SI) 
Homogeneous Heterogeneous 
Short axis ≤10mm >10mm 
Nodal contour Regular Irregular 
L/S Ratio ≥2 <2 
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Table 3: Localization and number of lymph nodes (n=53) on DWI  
 
 No 
External iliac proximal 
Right 
Left 
 
14 
5 
External iliac distal 
Right 
Left 
 
10 
10 
Internal iliac proximal 
Right 
Left 
 
1 
0 
Internal iliac distal 
Right 
Left 
 
0 
0 
Obturatory 
Right 
Left 
 
6 
6 
Common iliac  
Right 
Left 
 
1 
0 
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Table 4: Demographic and biometric information (patients n=5) 
 
Patients, N 5 
Age; mean (range) 67,2 (56-76) 
Preoperative PSA, mean (range)  17 (6-35) 
Biopsy Gleason grade  
6 (3+3)  
7 (3+4) 3 
7 (4+3)  
8 (4+4) 1 
9 (4+5) 1 
9 (5+4)  
Dissected lymph nodes, n 84 
Lymph node count, mean (range) 16,8 (12-23) 
Dissected nodal stations, n 46 
Metastatic nodal stations, n/N (%)  7/46 (15) 
Non-metastatic nodal stations, 
n/N (%) 
39/46 (85) 
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Table 5: Result of Grading Score per nodal stations (n=28) analysis     
 
Benign LN stations 
Score 
Malignant LN 
stations Score 
5,33 7 
5,33 6,5 
6 6,25 
4 6 
5,5 7 
5 6,5 
5 6 
5  
5  
5  
5  
4  
4  
5  
5,5  
5,28  
6  
5  
5  
5,5  
4  
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Table 6: Results of identifiable nodes on DWI (5 patients) (n=53)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Histologically 
metastatic 
Histologically 
benign 
P-value 
 
No. of nodal stations 7 21  
ADC value 
Mean ± SD 
range 
 
0.796 ± 0,09 
0,71-0,88 
 
1,17 ± 0,25 
1,05-1,28 
 
0,0008 
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Table 7: The receiver operating curve (ROC) showed the area under the curve (AUC) of 
0.96. 
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Table 8: Results of MRI according to the apparent diffusion coefficient (ADC) map per 
nodal stations (NS, n=28) analysis.    ADC*: x10-3 mm2/s 
Benign NS 
ADC* value 
Malignant NS 
ADC* value 
1,19 0,81 
1,22 0,84 
0,64 0,91 
1,1 0,63 
1,1 0,79 
0,96 0,83 
1,35 0,76 
1  
1,4  
0,95  
1,35  
1,95  
1,15  
1,37  
1,08  
1,16  
1,28  
1,11  
1,15  
1  
0,98  
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Table 9: Results of MRI according to the apparent diffusion coefficient (ADC) map per 
nodal stations (n=28) analysis     
                                  
                        DWI                                                     Histopathology 
 Positive Negative 
ADC ≤ 0,91x10-3 mm2/s 7 1 
ADC > 0,91x10-3 mm2/s 0 20 
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Figures 
 
Fig. 1: An example of benign lymph node. a. T2w image. b. DW image c. ADC map  
d. Grading score = 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                              36
Fig. 2: An example of metastatic lymph node. a. T2w image. b. DW image c. ADC map  
d. Grading score = 7. 
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Fig. 3 An example of metastatic lymph node. a. T2w image. b. DW image c. ADC map  
d. Grading score = 7. 
 
 
  
 
 
 
 
